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Running title :  
OCT in ARSACS 
Abstract    
Autosomal recessive spastic ataxia of Charlevoix-Saguenay is a rare neurodegenerative 
disorder caused by mutations in the SACS gene. Thickened retinal nerve fibres visible on 
fundoscopy have previously been described in these patients, however thickening of the 
retinal nerve fibre layer as demonstrated by optical coherence tomography appears to be a 
more sensitive and specific feature. To test this observation, we assessed 292 individuals (191 
patients with ataxia & 101 controls) by peripapillary time-domain optical coherence 
tomography. The patients included 146 with a genetic diagnosis of ataxia (17 autosomal 
spastic ataxia of Charlevoix-Saguenay, 59 Friedreich’s ataxia, 53 spinocerebellar ataxias, 17 
other genetically confirmed ataxias) and 45 with cerebellar ataxia of unknown cause. The 
controls included 13 asymptomatic heterozygotes for SACS mutations and 88 unaffected 
controls. The cases with autosomal recessive spastic ataxia of Charlevoix-Saguenay included 
eleven previously unpublished SACS mutations, of which seven were nonsense and four 
missense mutations. Most patients were visually asymptomatic and had no previous history 
of ophthalmic complaints and normal or near normal visual test results. None had visual 
symptoms directly attributable to the retinal changes. Twelve of the 17 cases (70.6%) had 
thickened retinal nerve fibres visible on fundoscopy.  All the autosomal recessive spastic 
ataxia of Charlevoix -Sagueney patients had thickening of the peripapillary retinal nerve fibre 
layer on optical coherence tomography, whereas all the remaining cases and controls except 
one showed normal or reduced average peripapillary retinal nerve fibre layer thickness on 
optical coherence tomography. We propose a cut-off value of 119m in average peripapillary 
retinal nerve fibre layer thickness which provides a sensitivity of 100% and specificity of 
99.4% amongst patients affected with ataxia. This is the largest cohort of patients with this 
condition to undergo systematic evaluation by optical coherence tomography. This is a useful 
tool in identifying cases of autosomal recessive spastic ataxia of Charlevoix-Saguenay from 
other causes of ataxia. Visualization of thickened retinal fibres by direct fundoscopy is less 
sensitive. We therefore advocate the use of this technique in the assessment of possible cases 
of this condition.    
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MLPA Multiplex Ligation-dependent Probe Amplification 
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Introduction   
 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS ; OMIM 270550) is a 
rare neurodegenerative disorder characterized by a slowly progressive cerebellar ataxia, 
spasticity and demyelinating peripheral neuropathy, causing incoordination, dysarthria, 
cerebellar eye signs, limb weakness, muscle cramps, distal amyotrophy, sensory loss, 
pyramidal signs and skeletal foot abnormalities. The condition was first described in the late 
1970s amongst founder populations in the Charlevoix and Saguenay-Lac-St-Jean regions of 
North-Eastern Québec but cases have subsequently been identified around the world.  The 
causative gene on chromosome 13q12.12 is named SACS and was identified in 2000 (Engert 
et al., 2000) with an open reading frame of 13,737 base pairs (Ouyang et al., 2006). More 
than 100 different mutations have now been described (Thiffault et al., 2013).  
 
The large number of mutations meant that diagnostic testing previously required Sanger 
sequencing of the entire gene. Custom panel next generation sequencing techniques are 
transforming this field and are becoming less expensive and more available year by year. 
However, they are still not available in many centres. Given the large quantity of genetic 
information produced by these techniques, it is more important than ever to have clinical tests 
which guide focused genetic testing. In addition, new genetic variants from next generation 
sequencing techniques can be challenging to interpret regarding pathogenicity. Further deep 
phenotyping, including supportive clinical tests, is vital whilst awaiting reliable functional 
studies to interpret new genetic variants. In the field of ARSACS, it appears that optical 
coherence tomography (OCT) may be an important supportive clinical test. 
 
OCT is used by ophthalmologists to investigate retinal disease and optic neuropathy. 
Thinning of the peripapillary retinal nerve fibre layer (RNFL) is seen in glaucoma, optic 
nerve inflammation, ischaemia and compression, as well as in multiple sclerosis, Alzheimer’s 
disease, Parkinson’s disease, hereditary spastic paraparesis type 7 (SPG7), epilepsy and with 
various drugs such as vigabatrin (Jindahra et al., 2010, Balestrini et al., 2016, Clayton et al., 
2011, Klebe et al., 2012). RNFL thinning has been demonstrated in the cerebellar subtype of 
multiple system atrophy (MSA-C) and spinocerebellar ataxia (SCA) types 1,2,3,6 and 7 (Pula 
et al., 2011, Manrique et al., 2009). In Friedreich’s ataxia, RNFL thinning correlates both 
with markers of clinical severity and the underlying genetic process (Fortuna et al., 2009, 
Noval et al., 2012, Seyer et al., 2013). Thus, thinning of the peripapillary RNFL appears to 
be a common feature of neurodegenerative disease, even in patients with little or no evidence 
of visual dysfunction. 
 
By contrast, thickening of the RNFL is generally only seen in conditions causing a swollen 
optic disc, such as the acute stage of inflammatory or ischaemic optic neuropathy, Leber’s 
hereditary optic neuropathy, papilloedema or central retinal vein occlusion (Karam and 
Hedges, 2005, Savini et al., 2006, Barboni et al., 2005). Patients with retinitis pigmentosa 
also have RNFL thickening (Hood et al., 2009), although in these cases there is gross 
disruption to the outer retinal layers making interpretation of these RNFL measurements 
unclear.  RNFL thickening is therefore not normally seen in the context of chronic 
progressive neurodegenerative disease. ARSACS may be an exception to this rule.  
 
The earliest clinical descriptions of ARSACS recorded ‘striking and markedly increased 
visibility of the retinal nerve fibers, mainly in the papillomacular bundle area’ (Bouchard et 
al., 1978). However these fundoscopic appearances have been inconsistently observed in 
non-Québecois cases (Takiyama, 2006, Gücüyener et al., 2001, Mrissa et al., 2000, Grieco et 
al., 2004, Garcia-Martin et al., 2013, Vermeer et al., 2008). OCT scans in ARSACS have 
confirmed abnormal thickening of the RNFL (Garcia-Martin et al., 2013, Vingolo et al., 
2011, Pablo et al., 2011, Desserre et al., 2011, Stevens et al., 2013, Nethisinghe et al., 2011, 
Gazulla et al., 2012) although one series reported a single case with peripapillary RNFL 
thicknesses of 86 and 111m which were within the range for unaffected controls (Yu-Wai-
Man et al., 2014). Furthermore, in a previous study we reported that two unaffected 
individuals in a single family who were heterozygous for two different SACS mutations 
showed partial peripapillary RNFL thickening with a mean of thickness of 115.5m 
(Nethisinghe et al., 2011). This finding has recently been confirmed in five heterozygotes for 
two different mutations which showed average peripapillary RNFL thickness of between 104 
and 132μm (Van Lint et al., 2016). 
 
It is therefore not clear whether RNFL thickening as detected by OCT is present in all cases 
of ARSACS, nor is it known whether similar OCT changes may be seen in patients with 
other non-ARSACS causes of ataxia or heterozygous carriers of SACS mutations ( Parkinson 
et al., 2014).  To address these questions, we measured RNFL thickness by OCT in ataxia 
patients who were referred to our tertiary hospital specialist ataxia centre and compared them 
with a large cohort of controls that included first degree relatives of known patients with 
ARSACS. 
 
Subjects and methods 
 
Study population and genetic analysis 
Patients were recruited from the Ataxia Centre of the National Hospital for Neurology and 
Neurosurgery (NHNN) in London UK, which receives referrals for specialist opinions from 
across the UK and internationally. The majority of patients live in London and the Southeast 
of England and are of UK descent. All patients gave informed consent, and the study was 
given approval by the London Brent Research Ethics Committee (reference 12/LO/1291) and 
complied with the Declaration of Helsinki. In total, 292 individuals were assessed including 
191 patients with ataxia and 101 controls. The 101 controls included 88 unaffected 
individuals and 13 unaffected first degree relatives of patients subsequently diagnosed in the 
study with ARSACS (and subsequently confirmed as heterozygotes for SACS gene 
mutations).  
 
At the commencement of the study, of the 191 patients with ataxia, 59 had a genetic 
diagnosis of Friedreich’s ataxia (FRDA) and 53 had various SCAs. The remaining 79 did not 
have a genetic diagnosis. All 191 had OCT scans and those that showed RNFL thickening (as 
defined as average peripapillary RNFL thickness above the 95th centile of the scanner’s 
normative data) underwent genetic analysis in the Department of Human Genetics, Radboud 
University, Nijmegen Medical Centre, Nijmegen, Netherlands, using previously described 
methods (Vermeer et al., 2008). DNA was extracted from peripheral blood lymphocytes 
using standard procedures. All cases were extensively investigated with biochemical, 
metabolic, genetic and other tests showing no evidence of an alternative diagnosis (see 
Supplementary Table 2). This revealed the 17 cases of ARSACS discussed in the study. 
SACS gene variants were annotated according to reference sequence NM_014363. 
 
The remainder continued to undergo routine genetic testing in our institution which revealed 
13 cases of various genetically determined ataxias (ataxia with oculomotor apraxia type 2 
(AOA2), episodic ataxia types 1 & 2 (EA1/2), fragile X tremor ataxia syndrome (FXTAS), 
ataxia with fibroblast growth factor mutation (FGF), Sjögren-Larsson syndrome (SLS) and 
ataxia with co-enzyme Q10 deficiency (ACoQ10D). The patient with ACoQ10D had a 
pathogenic mutation in the aarF domain-containing kinase 3 gene (ADCK3). 
 
The remaining 49 cases with no genetic diagnosis were subjected to an Illumina TruSeq 
Custom Amplicon panel (Illumina, San Diego, CA USA) covering 10 genes known to cause 
spastic ataxia (see Supplementary Table 1). Library preparation was undertaken using the 
manufacturer’s protocol (part 15027983, revision C, August 2013) using MiSeq reagent kit 
version 3 with amplicons designed to cover SACS gene exons with 99% coverage. 
Subsequent amplification used the polymerase chain reaction (PCR) according to the 
manufacturer’s protocol (Applied Biosystems Gene Amp PCR System 9700, Thermo Fisher 
Scientific, Waltham, MA USA) and massively parallel sequencing used the MiSeq sequencer 
(Illumina, San Diego, CA USA). This technique revealed four cases of SPG7. The 13 
heterozygous SACS gene carriers were also diagnosed using this technique. This left 45 cases 
of cerebellar ataxia of unknown cause. These patients had previously been assessed routinely 
in the NHNN Ataxia Centre and undergone extensive clinically appropriate genetic, 
metabolic and other diagnostic tests (see Supplementary Table 1). The demographic details 
and diagnoses of all patients are given in Table 1.   
 
Optical coherence tomography  
After dilating the pupils with 1% tropicamide eyedrops, the patients were seated at a time-
domain OCT (TD-OCT) device (Stratus, Carl Zeiss Meditec, Dublin, CA) and asked to fixate 
on the device’s internal target using the test eye whilst the fellow eye was occluded.  
Polarization was machine-optimised then the RNFL thickness was measured in a circle 
around the optic disc using the ‘Fast RNFL Thickness’ acquisition protocol.  OCT data were 
analysed using the proprietary software (Stratus version 4.07) which provides automated 
estimates of RNFL thickness in each quadrant around the disc (superior, nasal, inferior and 
temporal) and an average measurement of RNFL thickness around the entire circumference 
of the optic disc.  The analysis software also provides a measure of scan quality referred to as 
‘signal strength’ on an arbitrary scale 0-10; we took the decision to accept recordings only if 
the signal strength was at least 5, the scan circle was well-centred on the optic disc and there 
was no blink artefact. In each patient OCT scans were repeated three times per eye, and the 
results for both eyes averaged. In a small number of cases, imaging of both eyes was not 
possible for technical reasons such as inability to fixate or poor image quality. 
 
Clinical examination  
Each participant with ARSACS underwent full neurological examination by a neurologist 
experienced in the assessment of patients with ataxia (MHP) using a standard protocol. Age 
at onset was taken as the age of first symptoms compatible with the subsequent diagnosis of 
ARSACS as judged by the patient or in the medical notes. Patients had their best corrected 
visual acuity (Snellen) and colour vision (Ishihara pseudo-isochromatic plates) tested in both 
eyes, and then underwent a full ophthalmic examination by an experienced ophthalmologist 
(FB) including fundoscopy to determine whether there was clinically apparent abnormal 
thickening of the RNFL. 
 
Statistical analysis 
Statistical analysis was undertaken using IBM SPSS Statistics for Windows, version 21.0 
(IBM Corp., Armonk, NY, 2012) and Microsoft Excel (2010). Associations between RNFL 
thickness and disease duration, age at onset and age at examination were undertaken using 
linear regression analysis. Differences between RNFL thickness and visual scores between 
different patient groups were undertaken using analysis of co-variants (ANCOVA) with 
subsequent Mann-Whitney U-tests and Bonferroni correction. Calculations of sensitivity and 




Patients with ARSACS 
The 17 patients with ARSACS came from 11 families (see Table 2). The patients were 
between the ages of 21 and 62 when assessed. Disease onset varied between 1 and 46 years, 
and disease duration between 11 and 46 years. In contrast to previous descriptions of the 
Québecois cohort of ARSACS patients (Bouchard et al., 1998), members of one family 
(family D) had disease onset in middle life (range 35-51 years). All from this family share 
three pathogenic mutations, none of which is found in the Québecois population (Thiffault et 
al. , 2013). Two mutations (c.8339T>G and c.12416T>C; NM_014363.4) are known from 
studies of related carriers to cosegregate. All patients in the study had ataxia and all but one 
had spasticity (94.1%). Fourteen (82.4%) showed clinical evidence of sensory loss. Twelve 
(70.6%) had limb weakness. Deep tendon reflexes were absent in ten patients (58.8%) and 
hyperreflexic in six (35.3%), sometimes with mixed absent and increased reflexes in the same 
patient. Thirteen had extensor plantar reflexes (76.5%). Eleven patients had dysarthria 
(64.7%) and fifteen had skeletal foot abnormalities (88.2%). All patients displayed 
nystagmus.  
 
The 17 patients had 20 different sequence variants (see Table 2) of which nine have been 
published previously (c.1144G>T, c.4744G>T, c.5151dupA, c.5948C>T, c.6392delT, 
c.7255_7259delGAGAA, c.11265_11266delAT, c.11352_11353dupAA, c.12028C>T). Five 
variants were previously described in the thesis of Dr Sascha Vemeer (c.5820_5821delAC, 
c.7162_7163delAC, c.9404T>C, c.9956_9957delAA, c.11675C>G) (Vermeer, 2012) and six 
variants are novel (c. 3149C>A, c.4226_4229delATGA, c.6078delT, c.8339T>G, 
c.10115dupC, , c.12416T>C). Of these eleven, seven are pathogenic nonsense mutations. 
Four are missense variants involving single base pair substitutions (c.3149C>A, c.8339T>G, 
c.9404T>C, c.12416T>C) and amino acid changes (p.Ala1050Asp, p.Phe2780Cys, 
p.Leu3153Ser, p.Leu4139Ser; NP_055178.3). All are in the giant exon 10 of the SACS gene 
where the majority of mutations to date have been described. The lowest Grantham score was 
126 so that all amino acid changes were predicted to be radical or moderately radical. All 
four are predicted to affect highly conserved amino acids. All mutations were predicted to be 
disease-causing by Mutation Taster 2 software (http://www.mutationtaster.org/) and probably 
damaging by the Polymorphism Phenotyping Program 2 (PolyPhen2; 
http://genetics.bwh.harvard.edu/pph2/). The variants c.1349C>A and c.12416T>C were 
absent from the 1000 Genomes Project (1000G), the Exome Sequencing Project (ESP), the 
Database of Single Nucleotide Polymorphisms (dbSNP) and the Genome Aggregation 
Database (gnomAD). The variant c.9404T>C is recorded in ESP with a frequency of 0.00008 
and in gnomAD with a frequency of 0.00001. The variant c.8339T>G is present in all four 
databases including four homozygotes recorded in gnomAD suggesting that this variant is 
probably not pathogenic. Since c.8339T>G always co-segregated with c.12416T>C in 5 
siblings who have a nonsense mutation (c.11675C>G) on the other allele, this clarifies which 
of the two cis variants is pathogenic. Further details of the 20 mutations are given in 
Supplementary Table 3 and of the in silico pathogenicity prediction results for the four novel 
missense mutations in Supplementary Table 4. 
 
The results of the ophthalmological assessment of patients with ARSACS are given in Table 
2. In general, patients had no complaints about their eyes or vision.  In a few cases there was 
a history of previous ophthalmic problems (two patients with amblyopia, two with congenital 
colour blindness and one with myopia). No patients had visual symptoms ascribable to retinal 
disease, with 14/17 (82.4%) patients visually asymptomatic, one patient with diplopia, one 
with symptomatic nystagmus and one with focussing problems caused by keratoconus.  All 
patients except the patient with keratoconus had Snellen acuity of 6/9 or better, and only one 
patient was unable to identify the Ishihara pseudo-isochromatic plates correctly.  In all cases 
pupillary reactions to light were normal.  Apart from the one case with keratoconus, no other 
ARSACS patient was found to have any abnormality in the anterior segment of the eye on slit 
lamp biomicroscopy. 
 
Fundoscopy revealed abnormal thickening of the RNFL in 13/17 patients (76.5%). A typical 
example of this characteristic fundal appearance is shown in Fig. 1A: the peripapillary RNFL 
is thickened in all meridians and the abnormality extends for several disc diameters, 
obscuring in some places the retinal vessels. None of these cases had any associated swelling 
or elevation of the optic nerve head, nor were there any abnormalities seen in the overlying 
vitreous, retinal vessels, outer retina, retinal pigment epithelium or choroid.  In four of the 17 
cases of ARSACS (23.5%), fundoscopy was normal with no clinically apparent thickening of 
the RNFL; an example is shown in Fig. 1B.  There was no clear correlation between genotype 
and retinal phenotype; indeed in family D, individuals sharing the same mutations had 
different fundoscopic appearances. 
 
OCT measurements of the peripapillary RNFL thickness in these ARSACS patients are 
shown in Table 2 (for each patient figures shown are the mean of measurements from both 
eyes unless it was only possible to obtain a scan from one eye). The average peripapillary 
RNFL thickness measurements (estimated from the entire 3600 of the scanned circle around 
each disc) ranged from 119.3m to 174.8m, and in all cases lay above the 95% upper limit 
defined in the normative database provided by the manufacturer. OCT measurements of 
average peripapillary RNFL thickness were significantly lower in the four cases where 
fundoscopy was clinically normal (mean=130.2, sd=8.6) than in the remaining 13 cases 
where it was visibly thickened (mean=156.1, sd=12.3; p=0.001).  Further analysis of OCT 
measurements by quadrant (superior, nasal, inferior and temporal) showed similar degrees of 
abnormal thickening of the RNFL in all meridians.  Among the whole cohort of 17 patients 
with ARSACS there was a significant decline in average peripapillary RNFL thickness with 
age (linear regression coefficient R=0.624, p=0.007) and a negative correlation with age at 
onset (linear regression coefficient R=0.629, p=0.007) but a non-significant positive 
correlation with disease duration (linear regression coefficient R=0.368, p=0.146; see Fig. 2).  
 
Average OCT measurements of the peripapillary RNFL thickness for ARSACS and all other 
groups studied are shown in Table 1 and displayed as box-and-whisker plots in Fig. 3. A 
typical example of an OCT scan in an ARSACS patient is given in Fig. 1(C).  
 
SACS gene mutation heterozygotes 
Thirteen individuals carrying heterozygous SACS gene mutations who were all first-degree 
relatives of the patients studied had RNFL thickness measured by OCT. Twelve had visual 
acuity (VA) measured, of which two readings were less than 6/9. Eight had colour vision 
measured of which all were normal or near-normal. Mean RNFL thickness was 93.8μm with 
a range of 82.0 to 105.5μm. 
 
Patients with other types of genetic ataxia 
One hundred and twenty-nine patients with genetically confirmed ataxias other than 
ARSACS were seen (FRDA n=59, SCA n=53, others n=17). Many but not all of these 
patients had average peripapillary RNFL thickness measurements below the 95% lower limit 
of normal compared to the machine’s age-matched bank of normative data. None of these 
patients had average peripapillary RNFL measurements greater than 107m whereas all the 
ARSACS patients had RNFL measurements greater than 119m, providing an absolute 
differentiation between cases of ARSACS and other genetically proven ataxias. However, it 
is important to calculate average peripapillary RNFL thickness, as individual sectoral values 
may have greater and overlapping ranges (eg for the temporal quadrant, the lowest ARSACS 
value is 78.5m, whereas the highest non-ARSACS value is 150.5m for a patient with 
SCA3). There were no significant differences in gender between the seven groups (Pearson χ2 
value 7.939 with 6 degrees of freedom, p=0.243) but there were significant differences in age 
between the groups (ANOVA p<0.0005). In particular, the mean age of FRDA patients was 
significantly less than all other groups except the ARSACS patients. The only significant 
difference in age between the ARSACS group and any other group was with the SCA group 
(p=0.02, Mann-Whitney U test with Bonferroni correction). Using an ANCOVA corrected 
for age (covariates evaluated at 45.1 years) with Bonferroni correction for multiple tests 
showed that mean peripapillary RNFL thickness was significantly greater for the ARSACS 
group than all other groups (each p<0.0005). The FRDA group were significantly thinner 
than all other groups. In addition, the SCA group were significantly thicker than the 
unaffected controls (p=0.001). Table 3 shows the p-values 
 
Table 3: p-values for ANCOVA corrected for age with Bonferroni correction 
  SACS 
Hetero-
zygotes 







ARSACS <0.0005* <0.0005* <0.0005* <0.0005* <0.0005* <0.0005* 
SACS 
Heterozygotes 
 <0.0005* 0.692 1.0 1.0 1.0 
FRDA   0.001* 0.001* <0.0005* <0.0005* 
SCAs    1.0 0.107 0.001* 
Other genetic 
ataxias 




     1.0 
*significant at <0.05 
 
Fundoscopy was performed in 112 patients with other types of genetic ataxia. As expected, a 
number of typical abnormalities were seen including optic atrophy (in FRDA) and pigmented 
maculopathy (in SCA7), but none of these patients showed thickened RNFL similar to that 
seen in ARSACS. VA was measured in 88 patients (FRDA n=43, SCA n=34, others n=11). 
No significant differences survived Bonferroni correction for multiple analyses. Performance 
on Ishihara pseudo-isochromatic plates was assessed in 78 patients (FRDA n=35, SCA n=34, 
others n=9). There were no significant differences between groups and with ARSACS 
patients and heterozygotes, although unlike ARSACS patients and heterozygotes, there were 
patients in all 3 genetic groups who could not identify more than half of the plates. 
 
Patients with ataxia of unknown cause 
 
Forty-five patients were assessed, for whom no clear genetic or metabolic cause of ataxia 
including ARSACS had been identified, and none was a heterozygote for a SACS gene 
mutation. All patients except two had average peripapillary RNFL thickness below 110m 
with the lowest value being 45.5m. Twenty-two patients also had both Snellen visual acuity 
and Ishihara colour plates assessed. There were no significant differences in visual acuity or 
colour vision between the cases of unknown cause and any other group, although again, 
unlike the patients with ARSACS and SACS gene mutation heterozygotes, the group of cases 
of unknown cause included individuals with extremely poor vision.  
 
One patient showed average peripapillary RNFL thickness slightly above the lowest value for 
an ARSACS patient (119.3μm). There was no other ocular explanation for this slightly 
increased level of RNFL thickening (124.0μm). There were no point mutations in the SACS 
gene by the Illumina TruSeq Custom Amplicon technique described above. There was also 
no evidence of deletion or multiplication of SACS gene exons by multiplex ligation-
dependent probe amplification (MLPA; Dr Filippo Santorelli, personal communication). In 
addition, the case showed no mutations in a panel of genes known to cause spastic ataxia (see 
Supplementary Table 1) and was negative for SCA 1,2,3,6,7, FRDA, BSCL2, connexion-32, 





To our knowledge, this is the largest cohort of patients with ARSACS and other genetic 
ataxias to undergo systematic evaluation by OCT and comprehensive visual assessment. This 
study shows that OCT is a helpful tool in distinguishing ARSACS from other genetically 
diagnosed causes of progressive ataxia as well as cases of unknown cause and can therefore 
help to guide genetic testing. In our study, an average peripapillary RNFL thickness of 
119m on TD-OCT showed the greatest differentiation between ARSACS and other causes 
of ataxia. Amongst patients with symptomatic ataxia (ie ARSACS vs all other causes of 
ataxia), this gave a sensitivity of 100% and a specificity of 99.4% (area under ROC curve 
1.000, p<0.001), and a positive predictive value of 94.4%, a negative predictive value of 
100%, a false positive rate of 0.6% and a false negative rate of 0%.  
 
One case of ataxia of unknown cause had average peripapillary RNFL thickness just above 
this threshold (124.0μm). Spectral domain-OCT (SD-OCT) confirmed global RNFL 
thickening; however, the foveal architecture was normal in contrast to patients with 
genetically proven ARSACS where ganglion cells and their axons may be seen to extend 
across the fovea. This additional feature of the OCT evaluation may represent a means of 
distinguishing borderline cases. 
 
In addition, patients should first be thoroughly assessed to exclude acute causes of RNFL 
thickening such as LHON and optic neuritis. Fundoscopy should always be performed to 
exclude papilloedema and retinitis pigmentosa as other causes of thickened RNFL. Typically, 
ARSACS patients also do not have accompanying visual symptoms, other than those 
associated with cerebellar eye signs such as nystagmus. Thus, their presence should alert the 
clinician to an alternative diagnosis or an additional unrelated cause of ocular pathology. 
Similarly, patients diagnosed with ARSACS undergoing assessment in the neurology or 
ophthalmology clinics can be reassured that visual loss is rare in ARSACS and unrelated to 
RNFL thickening.  
 
In a previous publication from our group we reported mild thickening of the RNFL in two 
unaffected heterozygous carriers of SACS gene mutations (Nethisinghe et al., 2011). 
However, the average RNFL thickness in both these cases was 115.5μm which falls below 
the threshold found in this study (119μm) to distinguish ARSACS from non-ARSACS 
patients. Moreover, in the present study we have examined a further 13 heterozygous carriers 
of SACS gene mutations and in all cases the RNFL thickness was below 119μm.  
 
There was an inverse correlation between average peripapillary RNFL thickness and both age 
at examination and age at onset. However, there was only a trend toward, but not a 
statistically significant, positive correlation between average peripapillary RNFL thickness 
and disease duration. Peripapillary RNFL thickness is known to decrease very slowly by 0.18 
to 0.32μm/year in unaffected individuals (Girkin et al., 2011; Kim et al., 2011) due to decline 
in retinal ganglion cell axon numbers with age. This process is so slow in unaffected 
individuals that it is unlikely to interfere with the results in this study. The natural history of 
RNFL thickening in ARSACS patients is unknown. Whilst cross-sectional studies such as this provide 
some data relating to effects of age on RNFL thickness, longitudinal studies of RNFL thickness in 
ARSACS are required to answer this question definitively and may provide the identification of a 
novel biomarker. 
 
The underlying nature of the retinal changes seen in ARSACS remains unknown. Clinically, 
the thickened retinal nerve fibres appear as radial white or yellow streaks emanating from the 
optic disc, most commonly in the papillomacular region, and sometime obscuring the retinal 
vessels (see Fig. 1A). These have been described as ‘myelinated retinal fibers’ (Bouchard, 
1991) or ‘retinal hypermyelination’ (Prodi et al., 2013, Takiyama, 2006, Gücüyener et al., 
2001, Ogawa et al., 2004). However, to our knowledge there is no pathological or other 
evidence to support these appellations. Myelin is not normally present in the human retina. 
Myelination of optic nerve axons occurs by migration of oligodendrocyte progenitors along 
long axons, starting at the lateral geniculate body and ceasing at the lamina cribrosa of the 
optic nerve head where they are prevented from penetrating the retina probably by a dense 
aggregation of astrocytic processes (Hunter et al., 1997, Fitzgibbon and Nestorovski, 1997). 
The intraretinal course of the retinal ganglion axons is therefore not usually myelinated.  
 
However, myelinated axons are observed in the human retina in approximately 1% of the 
population (Straatsma et al., 1981), giving rise to the syndrome of (persistent) myelinated 
retinal nerve fibres (SMRNF). They usually cause a visual field defect, myopia or amblyopia 
(Tarabishy et al., 2007). When the eyes of patients with ARSACS are directly compared with 
those of patients with known myelinated retinal nerve fibres, a number of differences are 
apparent. In SMRNF, RNFL thickening is only seen where myelinated nerve fibres are 
visible, whereas in ARSACS RNFL thickening is widespread, including macula thickening, 
and is present even in subjects without visible RNFL thickening. In SMRNF, the myelinated 
nerve fibres cause posterior shadowing on OCT obscuring the deeper layers because of 
hyperreflectivity, but this feature is not seen in ARSACS. These findings suggest the material 
deposited in the retina is different in the two cases (Vingolo et al., 2011, Desserre et al., 
2011). We suggest the simple and descriptive term ‘thickened retinal nerve fibre layer’ 
(Nethisinghe et al., 2011) until their underlying nature is known. A greater understanding of 





OCT is a cheap, fast and widely available test which is sensitive and specific for identifying 
characteristic retinal changes in patients with ARSACS and can help in distinguishing 
ARSACS from other genetically diagnosed forms of ataxia and cases of unknown cause. We 
therefore advocate its routine use in the assessment of suspected cases of ARSACS even in 
the absence of fundoscopic changes. The underlying pathophysiology of these retinal changes 
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Figure & Table Legends 
 
Figure 1: Fundal appearance in ARSACS showing (A) peripapillary RNFL thickening 
apparent on fundal photography for patient 1 with RNFL of 175μm on OCT; and (B) RNFL 
thickening not apparent on fundal photography for patient 9 with RNFL of 139μm on OCT. 
(C) OCT appearance in ARSACS for patient 15 right eye showing thickening of RNFL 
(black line). The green band represents the 5th to 95th percentile of the normative data. 
(Quadrants: TEMP=temporal; SUP=superior; NAS=nasal; INF=inferior). 
 
  
Figure 2. Correlations between average peripapillary RNFL thickness among the ARSACS 
patients and (A) age at disease onset, (B) age at examination and (C) disease duration and 
average (n=17). Linear regression lines shown. 
 
 
Figure 3.  Box-and-whisker plots of average OCT measurements of peripapillary RNFL 
thickness in ARSACS, SACS gene mutation heterozygotes, FRDA, SCAs, other genetically 
confirmed ataxias, cerebellar ataxia of unknown cause, and unaffected controls. Boxes show 
median and interquartile range; whiskers show 5th and 95th percentiles; points show values 
outside 5th and 95th percentiles.   
 
Table 1: Demographic & OCT results by disease group  
 
Table 2: Neurological, ophthalmological & OCT results for ARSACS patients 
 
Table 3: p-values for ANCOVA corrected for age with Bonferroni correction 
 
Supplementary Table 1: Genetic tests for cases of ataxia of unknown cause 
 
Supplementary Table 2: Genetic tests for ARSACS patients 
 
Supplementary Table 1: SACS gene variants seen in ARSACS patients in OCT study 
 
Supplementary Table 2: In silico pathogenicity predictions for novel SACS gene missense  
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